script.reportAU
Sponsor

Bristol-Myers Squibb Australia

89 PBAC submissions on file, active 2006–2025. 75% have been recommended.

Submissions
89
2006 → 2025
Win rate
75 %
67 recommended of 89 bucketable
Drugs
24 · 21 listed
unique molecules submitted
PBS spend captured
$1.18B
FY-latest govt benefit on owned drugs

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

Therapy area mix

Oncology 58
Haematology 7
Cardiovascular 6
Endocrinology 6
Rheumatology 4
Hepatology 3
Infectious disease 1
Dermatology 1
Other 1
Gastroenterology 1

Activity by year

2006 (1) · 2007 (4) · 2010 (1) · 2011 (4) · 2012 (6) · 2013 (4) · 2014 (1) · 2015 (9) · 2016 (8) · 2017 (4) · 2018 (6) · 2019 (6) · 2020 (2) · 2021 (5) · 2022 (8) · 2023 (10) · 2024 (4) · 2025 (6)

Rejection patterns

Across 20 Not recommended decisions on file.

Open on full dashboard →